Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Vaccine trial aims to curb ‘superbug’

Sarah Le Roi knows well how debilitating Clostridium difficile infection (CDI) can be. She was struck down with the 'superbug' while on holiday in the US.

News & Events

Wesfarmers Centre of Vaccine and Infectious Diseases Research Seminar Series 2014

Wesfarmers Centre of Vaccine and Infectious Diseases Research Seminar Series 2014.Genetic and functional studies of leishmaniasis: understanding the role of HLA

News & Events

Infectious Disease & Vaccination Public Seminar

Hear the facts about vaccination and infectious disease from some of Australia's leading experts: Professor Jonathan Carapetis, Dr Peter Richmond

News & Events

WANTED: 'Flu Busters

Hundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.

News & Events

WA parents oblivious to true danger of the flu

Perth parents are underestimating the serious consequences of the flu, with only 19 per cent of children under five years of age currently immunized against the virus ahead of the peak winter flu season.

News & Events

The Kids Research Institute Australia researchers share in TPCHRF funding

Eight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).

Research

Vaccination

Vaccination is the injection of an inactivated bacteria or virus into the body. This simulated infection allows an individual's immune system to develop an adaptive immunity for protection against that type of illness. When a sufficiently large percentage of a population has been vaccinated, this results in herd immunity.

Research

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol

Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended. 

Research

Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference

Vaccination has been a cornerstone of public health, substantially reducing the global burden of infectious diseases, notably evident during the COVID-19 pandemic caused by SARS-CoV-2.

Research

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.